Health ❯ Healthcare ❯ Cancer Treatment

Immunotherapy

Checkpoint Inhibitors Pembrolizumab Personalized Medicine Immune Checkpoint Inhibitors Bispecific Antibodies mRNA Vaccines Combination Therapy Vaccine Development Tumor Microenvironment Patient Care

UCSF-Led Study Engineers CAR-T Cells In Vivo, Clearing Tumors in Mice

Researchers say the preclinical method now requires scaling followed by human trials.

ImmunityBio Shares Rise on ANKTIVA Surge, Saudi Approval for Lung Cancer

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

T Cell Receptor Switches From Closed to Open in Native Membrane, Rewriting Activation Model

GigaTIME AI Converts Routine H&E Slides Into Virtual Spatial Proteomics at Population Scale

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

Study Identifies TSP‑1–CD47 Signal That Drives T‑Cell Exhaustion in Cancer

Study Pinpoints Protein That Enables Drug-Triggered Rupture of Breast Cancer Cells

BioNTech Launches Exchange Offer for CureVac After German Antitrust Approval

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Tumor CRATERs Flag T-Cell Killing Hotspots and Track With Immunotherapy Response

Studies Show Lymph Nodes Sustain Stem-Like T Cells That Power Cancer Immunotherapy

IFITM3 Identified as Key Modulator of Immunotherapy Response in Small Cell Lung Cancer

Nankai Team Finds 15-Genus Tumor Microbiome Signature That Predicts GI Cancer Outcomes

Mexico’s Myeloma Care Lags as Late Diagnosis Undercuts Survival Gains

KRAS-Targeted Vaccine Shows Robust Immune Response, Longer-Than-Expected Survival in Pancreatic and Colorectal Cancer Trial

Off-The-Shelf KRAS Vaccine Yields Robust T-Cell Responses and Survival Benefit